Which one is preferable in NGS? Using different software for secondary and tertiary analyses or using one complete software package for both of the above? Waiting for some lights to be thrown of.............
-
-
software
There is no such thing that one tool/ software for all your needs. I have seen people doing mistakes. It will depend on what your questions are e.g in Chip seq histone modification and transcription factor are two different kinds of analysis though basic concept is similar (in layman- no of reads in a particular region) -
Hey Honey.. Thnx for your getting back on this.. I put the question from a different point of view..You have two options to go for:
1. You have a suite/ soft package which performs all basic analyses before going downstream, say, de novo assembly or reference guided alignment etc and also doing all those downstream analyses you are concern about (as you said, ChIP, gene expression analysis) in a interoperable manner.
2. You have to use a software for performing assembly, alignment etc and a different software for your concerned downstream experiment.
So, which one you would go for? A soft package or different soft?
So far I think, there may be some compatibility issues between output of a software and input of next required software, which have to be solved by some conversion tool.
Don't you think here researchers may face some troble in converting the formats?Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...Today, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment